Estevia, el edulcorante natural.

La estevia, Stevia rebaudiana (Bertoni) Bertoni, es una planta herbácea y perenne descrita por primera vez en 1889 por el naturalista Moisés Bertoni. Se trata de una especie originaria de la Región Oriental de Paraguay, donde los indígenas guaraníes la han usado tradicionalmente por sus aplicaciones edulcorantes y medicinales. La hoja fresca de estevia es de 10 a 15 veces más dulce que el azúcar común, la hoja seca y pulverizada lo es unas 70, mientras que los extractos lo son hasta 200 ó 300 veces más, debido a los glucósidos: esteviósido, rebaudósido A, B, C, D, E, dulcósido A y B y steviolbiósido. Entre las propiedades medicinales destacan las acciones hipotensora, antimicrobiana, dietética, digestiva e hipoglucémica, por lo que su uso está muy recomendado para personas afectadas de diabetes tipo 2. El cultivo de estevia ha adquirido importancia en algunos países como China, Paraguay o Brasil. Entre los principales consumidores se encuentran Japón, China, Malasia, Israel, Corea del Sur y Brasil. Sin embargo, en los países de la Unión Europea, por el momento, está denegado su uso como aditivo alimenticio o suplemento dietético

Análise crítica das técnicas de tratamento cirúrgico da obesidade mórbida

Introdução: A obesidade é uma afecção com alta prevalência no Brasil e no mundo. É fator de risco para comorbidades como Diabetes tipo 2 (DM2), Hipertensão Arterial Sistêmica (HAS), Dislipidemia, Apneia Obstrutiva do Sono (AOS), entre outras. Seu tratamento é complexo e a cirurgia bariátrica, executada por diferentes técnicas, tem sido uma das opções. Objetivo: Analisar os resultados publicados na literatura em relação às técnicas cirúrgicas de Banda Gástrica Ajustável (BGA), Gastrectomia Vertical (GV), Gastroplastia com derivação em Y de Roux (GDYR) e Derivação Biliopancreática (DBP) - técnica de \"Scopinaro\" e de \"Duodenal Switch\" quanto às complicações operatórias, à mortalidade, à perda do excesso de peso (PEP) e ao reganho, e a resolução das comorbidades após a operação. Método: Foram analisados 116 estudos selecionados na base de dados MEDLINE por meio da PubMed publicados na Língua Inglesa entre 2003 e 2014. Para comparar as diferentes técnicas cirúrgicas (BGA, GV, GDYR e DBP), realizou-se estudo estatístico por meio da análise de variância (ANOVA) aplicando os testes de Duncan e de Kruskal Wallis avaliando: complicações pós-operatórias (fístula, sangramento e óbito); perda e reganho do excesso de peso, e resolução das comorbidades. Resultados: A ocorrência de sangramento foi de 0,6% na média entre todos os estudos, sendo 0,44% na BGA; 1,29% na GV; 0,81% na GDYR e 2,09% na DBP. Já a ocorrência de fístulas foi de 1,3% na média entre todos os estudos, 0,68% para BGA; 1,93% para GV; 2,18% para GDYR e 5,23% para DBP. A mortalidade nos primeiros 30 dias pós-operatórios foi de 0,9% na média entre todos os estudos, 0,05% na BGA; 0,16% na GV; 0,60% na GDYR e 2,52% na DBP. A PEP após cinco anos na média entre todos os estudos foi de 63,86%, especificamente na BGA, foi de 48,35%; 52,7% na GV; 71,04% na GDYR e 77,90% na DBP. A taxa de DM2 resolvida foi de 76,9% na média entre todos os estudos, sendo 46,80% na BGA; 79,38% na GV; 79,86% na GDYR e 90,78% na DBP. A taxa de Dislipidemia resolvida após a operação foi de 74,0% na média de todo o estudo, sendo 51,28% na BGA; 58,00% na GV; 73,28% na GDYR e 90,75% na DBP. A taxa de HAS resolvida após a operação foi de 61,80% na média de todo o estudo, sendo 54,50% na BGA; 52,27% na GV; 68,11% na GDYR e 82,12% na DBP. A taxa de AOS resolvida após a operação foi de 75,0% na média de todo o estudo, sendo 56,85% na BGA; 51,43% na GV; 80,31% na GDYR e 92,50% na DBP. Conclusão: quando analisadas e comparada as quatro técnicas observa-se que nos primeiros 30 dias pós-operatório a taxa de sangramento é superior nos pacientes submetidos à DBP e taxa de fístula inferior nos pacientes da BGA. Quanto à mortalidade observou-se taxa mais pronunciada nos pacientes submetidos à DBP e menos nos submetidos à BGA. Quanto à PEP observou-se uma uniformidade entre os pacientes submetidos à GV, GDYR E DBP até o terceiro ano. Após esse período observa-se reganho de peso nos submetidos à GV até o quinto ano de seguimento. Já nos pacientes submetidos à BGA observou-se taxas de PEP menos pronunciadas em relação às demais desde o início do seguimento. Quanto à resolução das comorbidades observou-se taxas de resolução de DM2 inferiores nos pacientes submetidos à BGA, e não houve diferença entre nenhuma técnica quanto à resolução das demais comorbidades: HAS, AOS e dislipidemia

Tipo de bebidas consumidas por los estudiantes universitarios

Fundamentos: Existe una gran diferencia entre el consumo de agua y las bebidas que contiene agua (bebidas carbonatadas, azucaradas, zumos o bebidas alcohólicas). El consumo de estas bebidas está relacionado con el desarrollo de enfermedades crónicas (obesidad, diabetes tipo 2, hipertensión arterial o dislipemias). El objetivo es determinar la frecuencia de consumo de bebidas de los estudiantes de la Universidad de Alicante. Métodos: Estudio transversal descriptivo. Población 26.273 estudiantes. Se seleccionaron 396 mediante muestreo aleatorio simple. Se utilizó un cuestionario frecuencia consumo para estimar la ingesta individual. Variables: bebidas (n=12) y frecuencia de consumo (n=4). Resultados: El 29,6% de hombres y el 13,0% de mujeres consumen bebidas carbonatadas con azúcar a diario (p-valor<0,001). El consumo diario de vino es nulo. El 41,4% de la población consume cerveza y destilados semanalmente. El 76,1% de hombres y el 58,7% de mujeres, consumen alcohol como mínimo una vez a la semana, p-valor=0,001. Conclusiones: Los resultados plantean la necesidad de estudios epidemiológicos que orienten el desarrollo de políticas nutricionales dirigidas a reducir el consumo de bebidas azucaradas y alcohólicas entre la población joven. Mediante un trabajo conjunto entre las autoridades gubernamentales, medios de comunicación, industria alimentaria y la sociedad en general.

Influencia de enfermería en la educación para modificar estilos de vida en niños con sobrepeso y obesidad

La obesidad es una enfermedad crónica, compleja y multifactorial que suele iniciarse en la infancia y la adolescencia. La prevalencia de la obesidad está aumentando tanto en países en vías de desarrollado como en países desarrollados. Según la OMS, la obesidad está declarada como una epidemia global que incluye tanto a los niños como a la población adulta. La obesidad supone un mayor riesgo para enfermedades crónicas como la diabetes tipo 2, la enfermedad cardiovascular, hipertensión, accidente cerebrovascular y ciertas formas de cáncer. He llevado a cabo un estudio cualitativo, basándome en la investigación-acción, para modificar estilos de vida en adolescentes con obesidad y sobrepeso. Durante un periodo de dos meses, he realizado una observación participante en la consulta de pediatría de Atención Primaria de Novelda, para investigar los factores que intervienen en el desarrollo de la obesidad infantil entre niños de 10 a 13 años. Entre los factores externos más influyentes en el desarrollo de la obesidad, fueron el ambiente familiar, psicosocial y escolar. Para apoyar mi teoría, hice una búsqueda bibliográfica. Los resultados obtenidos en el estudio confirmaron la gran influencia que ejercen estos factores y por eso, la educación sanitaria es de gran importancia para que abarque todos ellos y se consiga una disminución del IMC en la población infantil.

Interventions against obesity through increased lipolysis in adipose tissue

Obesity is a disease of excess adiposity affecting> 17% of men and >20% of women in Britain. Clinically, it is defined by a Body Mass Index (BMI, kg/m2) of 2:30. Obesity is a confounding factor that promotes insulin resistance, hyperinsulinaemia and type 2 diabetes. Type 2 diabetes accounts for >90% of all cases of diabetes, with a prevalence of 2-6% of adults in most western societies, a majority of which are overweight or obese. Weight loss in obese patients reduces the risk of developing diabetes by >50%. This thesis has investigated the first part of a two-stage therapeutic intervention against obesity in which adipose tissue lipolysis will be combined with increased energy expenditure: the approach is also designed to consider agents that will benefit glycaemic control in coexistent obesity and diabetes by improving insulin sensitivity. Rodent and human in vitro models of adipocyte biology and skeletal muscle have been developed, characterised and evaluated. They include isolated epididymal and parametrial adipocytes of lean and obese diabetic ob/ob mice, cultured 3T3-Ll preadipocytes, isolated human omental and subcutaneous adipocytes and rat L6 cultured muscle cells. Compounds investigated for anti-obesity and anti-diabetic properties include M2 (sibutramine metabolite), 3-guanidinopropionic acid and mazindol. In vivo studies were undertaken to investigate these compounds further in lean and ob/ob mice. In vivo studies indicated that M2 and 3-guanidinopropionic acid reduced body weight gain in ob/ob mice. The three compounds increased lipolysis in adipocytes isolated from lean and ob/ob mice and human adipose depots. The direct action of these compounds was mediated via a pathway involving the f3 adrenoceptors and components of the lipolytic signalling pathway, including protein kinase A and p38 MAP kinase. In addition, M2 and mazindol were capable of increasing glucose uptake into insulin sensitive tissues. M2 and mazindol can act directly on adipose tissue and skeletal muscle to increase glucose uptake via a pathway involving new protein synthesis and activation of the glucose transporters. The M2-stimulated pathway is activated by the conversion of phosphatidylinositol bisphosphate to phosphatidylinositol trisphosphate by phosphatidylinositol 3-kinase. Thus, M2, mazindol and 3-GPA showed pharmacodynamic properties which suggested they might be potential therapeutic treatments for obesity and diabetes.

Milk feeding, solid feeding, and obesity risk:a review of the relationships between early life feeding practices and later adiposity

Childhood obesity is a major health issue with associated ill-health consequences during childhood and into later adolescence and adulthood. Given that eating behaviors are formed during early childhood, it is important to evaluate the relationships between early life feeding practices and later child adiposity. This review describes and evaluates recent literature exploring associations between child weight and the mode of milk feeding, the age of introducing solid foods and caregivers’ solid feeding practices. There are many inconsistencies in the literature linking early life feeding to later obesity risk and discrepancies may be related to inconsistent definitions, or a lack of control for confounding variables. This review summarizes the literature in this area and identifies the need for large scale longitudinal studies to effectively explore how early life feeding experiences may interact with each other and with nutritional provision during later childhood to predict obesity risk.

Avaliação do efeito do liraglutida nos tecidos muscular e adiposo e nos parâmetros bioquímicos em camundongos Swiss submetidos à dieta de cafeteria e a atividade física

Obesity is a chronic metabolic disease characterized by adipose tissue formation excess leading to an increase in body fat mass, of multifactorial origin, produced mainly by poor eating habits combined with a sedentary lifestyle. Data consider obesity as a serious disease that affects the world's population, ranking fifth in death rates. Faced with this situation, individuals seek, increasingly, means to lose weight with less physical effort and food. In 2009 and 2010 the drug liraglutide was lauched in order to reduce weight in individuals with diabetes mellitus type 2, thus avoiding the emergence of other diseases. The aggravating factor is that obese nondiabetic individuals are making use of this substance, even if its use is not authorized by ANVISA (Brazilian Health Surveillance Agency). Thus the objective of this research is to evaluate the effect of liraglutide for muscle or fat tissues and biochemical parameters in Swiss mice submitted to cafeteria diet and physical activity. The study was approved by the Ethics Committee on Animal Use - CEUA (nº003 Protocol / 2014). For this study 74 animals (Swiss mice) were used, divided as follows: in the initial phase of this study, we carried out a pilot study (n = 10) divided into a control group (PCON) (n = 5) and cafeteria group (PCAF) (n = 5), in order to evaluate a cafeteria diet which was both attractive to the animals and that could provide an increase in adipose tissue. After the induction of the diet, animals were euthanized and as a result, the animals in the PCAF group showed an intra-abdominal adiposity 0.74 ± 0.05 g, taken as the parameter for increasing fat in animals. Subsequently the study base was conducted for this research where animals were used (n = 64) divided into 2 groups: the Cafeteria Study Base Group (EBCAF) divided as follows: cafeteria + exercise + liraglutide (CEL) (n = 8), cafeteria + exercise + saline (CES) (n = 8), cafeteria + liraglutide (CL) (n = 8) and cafeteria + saline (CS) (n = 8). The Chow Study Base group (EBR) was divided into: exercise + liraglutide (EL) (n = 8), exercise + saline + (ES) (n = 8), liraglutide (L) (n = 8) and saline solution (SS) (n = 8). All animals went through the submission process to the cafeteria diet, followed by exercise protocol through swimming and treatment with the test substance intraperitoneally (200 mg / mL / kg). After the treatments, the animals were euthanized and had the following parameters evaluated: the muscle tissue mass, adipose tissue mass and biochemical parameters. It was observed that the processing done with the exercise-associated liraglutide reduced adipose tissue mass significantly (0.32 ± 0.05 g) compared to the saline group (0.53 ± 0.07 g). There were no changes in the muscle tissue of the group which was treated and exercised (1.39 ± 0.03 g) compared to the saline group (1.33 ± 0.03 g). Regarding biochemical parameters it was evident that there were changes in these parameters. Interesting to note that, although blood glucose values have been changed, the animals did not become diabetic. Thus, it appears that physical activity together with liraglutide is eficcient to the loss of intraabdominal adipose tissue and the maintenance of lean body mass thereby generating a satisfactory result in the pursuit of quality of life and disease prevention.

Avaliação do efeito do liraglutida nos tecidos muscular e adiposo e nos parâmetros bioquímicos em camundongos Swiss submetidos à dieta de cafeteria e a atividade física

Obesity is a chronic metabolic disease characterized by adipose tissue formation excess leading to an increase in body fat mass, of multifactorial origin, produced mainly by poor eating habits combined with a sedentary lifestyle. Data consider obesity as a serious disease that affects the world's population, ranking fifth in death rates. Faced with this situation, individuals seek, increasingly, means to lose weight with less physical effort and food. In 2009 and 2010 the drug liraglutide was lauched in order to reduce weight in individuals with diabetes mellitus type 2, thus avoiding the emergence of other diseases. The aggravating factor is that obese nondiabetic individuals are making use of this substance, even if its use is not authorized by ANVISA (Brazilian Health Surveillance Agency). Thus the objective of this research is to evaluate the effect of liraglutide for muscle or fat tissues and biochemical parameters in Swiss mice submitted to cafeteria diet and physical activity. The study was approved by the Ethics Committee on Animal Use - CEUA (nº003 Protocol / 2014). For this study 74 animals (Swiss mice) were used, divided as follows: in the initial phase of this study, we carried out a pilot study (n = 10) divided into a control group (PCON) (n = 5) and cafeteria group (PCAF) (n = 5), in order to evaluate a cafeteria diet which was both attractive to the animals and that could provide an increase in adipose tissue. After the induction of the diet, animals were euthanized and as a result, the animals in the PCAF group showed an intra-abdominal adiposity 0.74 ± 0.05 g, taken as the parameter for increasing fat in animals. Subsequently the study base was conducted for this research where animals were used (n = 64) divided into 2 groups: the Cafeteria Study Base Group (EBCAF) divided as follows: cafeteria + exercise + liraglutide (CEL) (n = 8), cafeteria + exercise + saline (CES) (n = 8), cafeteria + liraglutide (CL) (n = 8) and cafeteria + saline (CS) (n = 8). The Chow Study Base group (EBR) was divided into: exercise + liraglutide (EL) (n = 8), exercise + saline + (ES) (n = 8), liraglutide (L) (n = 8) and saline solution (SS) (n = 8). All animals went through the submission process to the cafeteria diet, followed by exercise protocol through swimming and treatment with the test substance intraperitoneally (200 mg / mL / kg). After the treatments, the animals were euthanized and had the following parameters evaluated: the muscle tissue mass, adipose tissue mass and biochemical parameters. It was observed that the processing done with the exercise-associated liraglutide reduced adipose tissue mass significantly (0.32 ± 0.05 g) compared to the saline group (0.53 ± 0.07 g). There were no changes in the muscle tissue of the group which was treated and exercised (1.39 ± 0.03 g) compared to the saline group (1.33 ± 0.03 g). Regarding biochemical parameters it was evident that there were changes in these parameters. Interesting to note that, although blood glucose values have been changed, the animals did not become diabetic. Thus, it appears that physical activity together with liraglutide is eficcient to the loss of intraabdominal adipose tissue and the maintenance of lean body mass thereby generating a satisfactory result in the pursuit of quality of life and disease prevention.

A cross-sectional study assessing the association between online ratings and structural and quality of care measures : results from two German physician rating websites

BACKGROUND: Even though physician rating websites (PRWs) have been gaining in importance in both practice and research, little evidence is available on the association of patients' online ratings with the quality of care of physicians. It thus remains unclear whether patients should rely on these ratings when selecting a physician. The objective of this study was to measure the association between online ratings and structural and quality of care measures for 65 physician practices from the German Integrated Health Care Network "Quality and Efficiency" (QuE). METHODS: Online reviews from two German PRWs were included which covered a three-year period (2011 to 2013) and included 1179 and 991 ratings, respectively. Information for 65 QuE practices was obtained for the year 2012 and included 21 measures related to structural information (N = 6), process quality (N = 10), intermediate outcomes (N = 2), patient satisfaction (N = 1), and costs (N = 2). The Spearman rank coefficient of correlation was applied to measure the association between ratings and practice-related information. RESULTS: Patient satisfaction results from offline surveys and the patients per doctor ratio in a practice were shown to be significantly associated with online ratings on both PRWs. For one PRW, additional significant associations could be shown between online ratings and cost-related measures for medication, preventative examinations, and one diabetes type 2-related intermediate outcome measure. There again, results from the second PRW showed significant associations with the age of the physicians and the number of patients per practice, four process-related quality measures for diabetes type 2 and asthma, and one cost-related measure for medication. CONCLUSIONS: Several significant associations were found which varied between the PRWs. Patients interested in the satisfaction of other patients with a physician might select a physician on the basis of online ratings. Even though our results indicate associations with some diabetes and asthma measures, but not with coronary heart disease measures, there is still insufficient evidence to draw strong conclusions. The limited number of practices in our study may have weakened our findings.

Molecular markers for diabetic nephropathy

Type 2 diabetes is one of the most common metabolic disorders in the world. Globally, the prevalence of this disorder is predicted to increase, along with the risk of developing diabetic related complications. One of those complications is diabetic nephropathy, defined by a progressive increase in proteinuria and a gradual decline in renal function. Approximately 25% to 30% of type 2 diabetic individuals develop this complication. However, its underlying genetic mechanisms remain unclear. Thus, the aim of this study is to contribute to the discovery of the genetic mechanisms involved in the development and progression of diabetic nephropathy, through the identification of relevant genetic variants in Portuguese type 2 diabetic individuals. The exomes of 36 Portuguese type 2 diabetic individuals were sequenced on the Ion ProtonTM Sequencer. From those individuals, 19 did not present diabetic nephropathy, being included in the control group, while the 17 individuals that presented the diabetic complication formed the case group. A statistical analysis was then performed to identify candidate common genetic variants, as well as genes accumulating rare variants that could be associated with diabetic nephropathy. From the search for common variants in the study population, the statistically significant (p-value ≤ 0.05) variants rs1051303 and rs1131620 in the LTBP4 gene, rs660339 in UCP2, rs2589156 in RPTOR, rs2304483 in the SLC12A3 gene and rs10169718 present in ARPC2, were considered as the most biologically relevant to the pathogenesis of diabetic nephropathy. The variants rs1051303 and rs1131620, as well as the variants rs660339 and rs2589156 were associated with protective effects in the development of the complication, while rs2304483 and rs10169718 were considered risk variants, being present in individuals with diagnosed diabetic nephropathy. In the rare variants approach, the genes with statistical significance (p-value ≤ 0.05) found, the STAB1 gene, accumulating 9 rare variants, and the CUX1 gene, accumulating 2 rare variants, were identified as the most relevant. Both genes were considered protective, with the accumulated rare variants mainly present in the group without the renal complication. The present study provides an initial analysis of the genetic evidence associated with the development and progression of diabetic nephropathy, and the results obtained may contribute to a deeper understanding of the genetic mechanisms associated with this diabetic complication.

Actividad hipoglucemiante de un extracto etanólico de las hojas de Hamelia patens “Chichipince” en ratones de cepa NIH

La presente investigación se realizó con el objetivo de determinar el efecto hipoglucemiante de un extracto etanólico de las hojas de Hamelia patens (chichipince) a tres diferentes concentraciones, las cuales fueron 100mg/kg, 250mg/kg y 500mg/kg de peso corporal. Para ello se emplearon modelos experimentales utilizándose ratones hembra albinos suizos NIH a los que se evaluaron en tres diferentes situaciones fisiológicas: a) normoglucémicos (sanos), b) Ante una sobre carga de glucosa (normoglucémicos), c) inducidos a diabetes mediante una serie de dosis bajas de Estreptozotocina (STZ). La determinación de los niveles de glucosa se realizó por medio de tiras reactivas, previo a un periodo de ayuno, extrayendo una muestra homogénea de sangre de cada animal experimental. Se encontró que el extracto etanólico de las hojas secas de Hamelia patens no presento ningún tipo de toxicidad en los sujetos experimentales durante su periodo de prueba. En cuanto a la actividad hipoglucemiante del extracto etanólico evaluado de Hamilia patens, no resulto efectivo para reducir los niveles de glucosa en sangre y por lo tanto no representa una alternativa para el tratamiento de la diabetes tipo 2

Prevalence, types and factors associated with echocardiographic abnormalities among newly diagnosed diabetic patients at Mulago Hospital.

Background: The prevalence of Diabetes mellitus (DM) is on a rise in sub-Saharan Africa and will more than double by 2025. Cardiovascular disease (CVD) accounts for up to 2/3 of all deaths in the diabetic population. Of all the CVD deaths in DM, 3/4 occur in sub Saharan Africa (SSA). Non invasive identification of cardiac abnormalities, such as Left Ventricular Hypertrophy (LVH), diastolic and systolic dysfunction, is not part of diabetes complications surveillance programs in Uganda and there is limited data on this problem. This study sought to determine the prevalence, types and factors associated with echocardiographic abnormalities among newly diagnosed diabetic patients at Mulago National referral hospital in Uganda. Methods: In this cross sectional study conducted between June 2014 and December 2014, we recruited 202 newly diagnosed adult diabetic patients. Information on patients\' socio-demographics, bio-physical profile, biochemical testing and echocardiographic findings was obtained for all the participants using a pre-tested questionnaire. An abnormal echocardiogram in this study was defined as the presence of LVH, diastolic and/or systolic dysfunction and wall motion abnormality. Bivariate and multivariate logistic regression analyses were used to investigate the association of several parameters with echocardiographic abnormalities. Results: Of the 202 patients recruited, males were 102(50.5%) and the mean age was 46±15 years. Majority of patients had type 2 DM, 156(77.2%) and type 1 DM, 41(20.3%) with mean HbA1C of 13.9±5.3%. Mean duration of diabetes was 2 months. The prevalence of an abnormal echocardiogram was 67.8 % (95% CI 60%-74%). Diastolic dysfunction, systolic dysfunction, LVH and wall motion abnormalities were present in 55.0%, 21.8%, 19.3% and 4.0% of all the participants respectively. In bivariate logistic regression analysis, the factors associated with an abnormal echocardiogram were age (OR 1.09 [95% CI 1.06–1.12], P <0.0001), type 2 DM (OR 5.8[95% CI 2.77-12.07], P<0.0001), hypertension (OR 2.64[95% CI 1.44-4.85], P=0.002), obesity (OR 3.51[955 CI 1.25-9.84], P=0.017 and increased waist circumference (OR 1.02[95% CI 1.00-1.04], P=0.024. On Multiple logistic regression analysis, age was the only factor associated with an abnormal echocardiogram (OR 1.09[95%CI 1.05-1.15], P<0.0001). Conclusion: Echocardiographic abnormalities were common among newly diagnosed adults with DM. Traditional CVD risk factors were associated with an abnormal echocardiogram in this patient population. Due to a high prevalence of echocardiographic abnormalities among newly diagnosed diabetics, we recommend screening for cardiac disease especially in patients who present with traditional CVD risk factors. This will facilitate early diagnosis, management and hence better patient outcomes.

Sensibilidad a la insulina mediante la prueba de tolerancia oral a la glucosa en adultos mayores en el cantón Cuenca, en el año 2015

INTRODUCCIÓN: Si se valora a tiempo la Sensibilidad a la insulina, se evitara padecer diabetes tipo 2; en los adultos mayores hay cambios como el aumento de tejido adiposo y sarcopenia, relacionados con disminución de la sensibilidad a la insulina. OBJETIVO: Determinar la sensibilidad a la insulina mediante la prueba de tolerancia oral a la glucosa en la población adulta mayor del cantón Cuenca, en el año 2015. METODOLOGÍA: Estudio descriptivo en 120 adultos mayores del cantón Cuenca; 60 casos con síndrome metabólico según el criterio ATP III y 60 casos sin síndrome metabólico. Se trata de una muestra no probabilística por conveniencia debido al costo de las pruebas de laboratorio. Se tomaron dos muestras de sangre una en ayunas y otra postprandial y se dosifico glucosa e insulina. Los datos fueron analizados en SPSS 22, Excel empleando frecuencias, porcentajes, medidas de tendencia central como mediana, promedio, medidas de dispersión, desvío stándar. RESULTADOS: El 39,2 % de adultos mayores presentó insulinemia postprandial alterada. Según el método HOMA-IR el 42 % presenta baja sensibilidad a la insulina y según el método QUICKI el 91,7 % presenta sensibilidad disminuida a la insulina. La baja sensibilidad a la insulina según género, edad y estado civil no fue significativa; en cambio con el IMC elevado se tiene más probabilidad de padecer insulinorresistencia (p=0,03) .Siendo más significativo los pacientes con síndrome metabólico aumenta dos veces la probabilidad de padecer insulinorresistencia (p=0.02, OR 2.3 IC 95% 1.09 – 4.85)

Correlación entre glucosa basal y hemoglobina glucosilada en el adulto mayor en el cantón Cuenca, 2015

INTRODUCCIÓN: Alteraciones en el metabolismo de la glucosa son causantes de Síndrome Metabólico y diabetes en adultos mayores; la determinación de hemoglobina glucosilada es un indicador exacto de la glucemia de los individuos en los últimos tres meses permitiendo comprobar el estado de salud. OBJETIVO: Establecer la correlación entre glucosa basal y hemoglobina glucosilada y su asociación con Síndrome Metabólico en adultos mayores del cantón Cuenca. METODOLOGÍA: Estudio descriptivo en 126 adultos mayores. Para la obtención de la muestra se utilizó el calculador automático EPI INFO. De los participantes un grupo con Síndrome Metabólico cumplió el criterio de la Adult Treatment Panel (APT-III). Se aplicó una encuesta para recolección de información y se tomó muestras de sangre para determinar glucosa basal y hemoglobina glucosilada. La información obtenida se procesó en el programa SPSS versión 20.0, Excel y MedLab. Se clasificaron los valores de acuerdo a frecuencia por edad, sexo y su relación con Síndrome Metabólico. RESULTADOS: Se analizaron 126 pacientes entre 65 y 96 años, siendo más frecuentes adultos mayores de sexo femenino con 65,1%. La población con Síndrome Metabólico fue 50.8%. La media de glucosa fue 87,16 y de hemoglobina glucosilada 5,65%. Luego del análisis 92% se encontraron en el rango normal de glucemia y 92,8% de HbA1; se ubicó en el rango de prediabetes 4,8% y dentro del rango de diabetes el 2,4%. Mediante coeficiente de correlación de Pearson se determinó una correlación moderada de 0.418 entre glucemia basal y hemoglobina glucosilada. Se observó una ligera relación entre alteración del metabolismo de glucosa y Síndrome Metabólico pues 12,5% de pacientes con esta enfermedad presentaron hiperglucemia y 11% HbA1 alterada

Sensibilidad a la insulina mediante la prueba de tolerancia oral a la glucosa en adultos mayores en el cantón Cuenca, en el año 2015

INTRODUCCIÓN: Si se valora a tiempo la Sensibilidad a la insulina, se evitara padecer diabetes tipo 2; en los adultos mayores hay cambios como el aumento de tejido adiposo y sarcopenia, relacionados con disminución de la sensibilidad a la insulina. OBJETIVO: Determinar la sensibilidad a la insulina mediante la prueba de tolerancia oral a la glucosa en la población adulta mayor del cantón Cuenca, en el año 2015. METODOLOGÍA: Estudio descriptivo en 120 adultos mayores del cantón Cuenca; 60 casos con síndrome metabólico según el criterio ATP III y 60 casos sin síndrome metabólico. Se trata de una muestra no probabilística por conveniencia debido al costo de las pruebas de laboratorio. Se tomaron dos muestras de sangre una en ayunas y otra postprandial y se dosifico glucosa e insulina. Los datos fueron analizados en SPSS 22, Excel empleando frecuencias, porcentajes, medidas de tendencia central como mediana, promedio, medidas de dispersión, desvío stándar. RESULTADOS: El 39,2 % de adultos mayores presentó insulinemia postprandial alterada. Según el método HOMA-IR el 42 % presenta baja sensibilidad a la insulina y según el método QUICKI el 91,7 % presenta sensibilidad disminuida a la insulina. La baja sensibilidad a la insulina según género, edad y estado civil no fue significativa; en cambio con el IMC elevado se tiene más probabilidad de padecer insulinorresistencia (p=0,03) .Siendo más significativo los pacientes con síndrome metabólico aumenta dos veces la probabilidad de padecer insulinorresistencia (p=0.02, OR 2.3 IC 95% 1.09 – 4.85).